Skip to main content

Ulcerative Colitis clinical trials at UCLA

2 in progress, 1 open to eligible people

Showing trials for
  • Hyperbaric Oxygen Therapy for Ulcerative Colitis

    open to eligible people ages 18-85

    Chronic intestinal hypoxia and accompanying mucosal inflammation is a hallmark of ulcerative colitis (UC). Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen under increased atmospheric pressure to increase tissue oxygenation. Two small prospective randomized controlled trials have demonstrated that the delivery of HBOT to UC patients hospitalized for acute moderate to severe flares results in improved remission rates and avoidance of in-hospital progression to biologics, small molecules, or colectomy. In this larger trial the study aims to confirm the treatment benefits of HBOT for hospitalized UC patients and study the immune-microbe mechanisms underpinning treatment response.

    Los Angeles, California and other locations

  • Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis

    Sorry, in progress, not accepting new patients

    The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis (UC).

    Los Angeles, California and other locations

Our lead scientists for Ulcerative Colitis research studies include .

Last updated: